Spectrum Pharmaceuticals, Inc.

SPPINASDAQHealthcare

$1.03

$-0.01(-0.49%)

Market Cap$210377146

P/E Ratio—

52W High$1.57

52W Low$0.32

Avg Volume1.2M

Open$1.02

Beta2.14

Free Cash Flow Financials Revenue

Spectrum Pharmaceuticals, Inc. (SPPI) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SPPI · free cash flow · updated Jun 9, 2026

Core FCF metrics

SPPI · FCF · TTM · margin & CAGR

Free cash flow was −$97.3M for FY2022 (fiscal year ending 2022-12-31), up 18.7% year-over-year The FCF margin was -961.7%.

FY2022 Free Cash Flow−$97.3M▲ +18.7% YoY

Trailing 12M (TTM)−$88.5Mtrailing 4 quarters sum

FCF Margin-961.7%−$97.3M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SPPI · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$97.0M(0M)−$97.3M▲ +18.7%-961.7%

FY2021−$119.5M(0M)−$119.7M▲ +5.9%—

FY2020−$121.6M(6M)−$127.2M▲ +11.5%—

FY2019−$134.6M(9M)−$143.6M▼ 120.5%-635.2%

FY2018−$62.4M(3M)−$65.2M▼ 65.7%-59.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SPPI · P/FCF · FCF yield · FCF per share

Spectrum Pharmaceuticals, Inc. (SPPI) reported negative free cash flow of −$0.10B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

SPPI · cash flow statement · operating / investing / financing

For FY2022, Spectrum Pharmaceuticals, Inc. generated −$97.0M in operating cash flow and spent 0M in capital expenditures, yielding −$97.3M in free cash flow.

Operating Activities

−$97.0M

Cash from core business operations

2022-12-31

Investing Activities

−$26.7M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$75.6M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$97.0M) − |CapEx| (0M) = FCF (−$97.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SPPI vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Spectrum Pharmaceuticals, Inc.YOU

SPPI

−$97.3M+18.7%-961.7%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Spectrum Pharmaceuticals, Inc. (SPPI) reported free cash flow of −$97.3M for FY2022 (fiscal year ending 2022-12-31), up 18.7% year-over-year. The FCF margin was -961.7%.

Based on available data, Spectrum Pharmaceuticals, Inc. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $46.2M in FY2012.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SPPI free cash flow · 8 questions

Spectrum Pharmaceuticals, Inc. free cash flow was −$97.3M for FY2022, up 18.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$88.5M.

SPPI free cash flowSPPI FCFSPPI FCF 2022SPPI free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Spectrum Pharmaceuticals, Inc. · Spectrum Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026